pegylated recombinant human arginase (BCT-100)

News alerts, weekly reports and conference planners

Company:

BCT international

Drug class:

Arginase replacement

Related drugs:

‹

›

ASS1 negative	Hepatocellular Cancer	ASS1 negative	Hepatocellular Cancer	BCT-100 Sensitive: C3 – Early Trials BCT-100 Sensitive : C3	BCT-100 Sensitive: C3 – Early Trials BCT-100 Sensitive : C3
ARG2 underexpression	Small Cell Lung Cancer	ARG2 underexpression	Small Cell Lung Cancer	BCT-100 Sensitive: D – Preclinical BCT-100 Sensitive : D	BCT-100 Sensitive: D – Preclinical BCT-100 Sensitive : D

Associations
(2)